推进早期和公平检测痴呆症:关键的学习/挑战,最近的创新,以及未来的方向
Joshua Chodosh1,2, Soo Borson3,4, Alexandra Nordyke1
1Division of Geriatric Medicine and Palliative Care, New York University Grossman School of Medicine, New York, New York, United States.
The Gerontologist
|October 1, 2025
概括
全球超过一半的痴呆症患者仍未被诊断出来,在种族,种族和经济群体之间检测的差异很大. 早期发现痴呆症是一个关键的公共卫生问题,需要全系统协调努力.
科学领域:
- 公共卫生 公共卫生
- 神经学 神经学
- 健康 公平 卫生 公平
背景情况:
- 在全球范围内,超过50%的痴呆病例没有被诊断出来,这突显出一个重大的公共卫生挑战.
- 在美国,种族,民族和经济差异导致错过或延迟痴呆症诊断的比率更高,特别影响少数群体和弱势群体.
- 与非西班牙裔白人个人相比,非西班牙裔黑人和拉丁裔个人中延迟诊断更为常见.
研究的目的:
- 强调早期发现痴呆症作为公共卫生优先事项的重要性.
- 倡导有系统地努力提高痴呆症检测率和诊断质量.
- 促进对早期痴呆症检测的公共卫生战略的理解和实施.
主要方法:
- 全球和国家痴呆症诊断率的系统审查.
- 分析跨种族,种族和经济群体的诊断差异.
- 描述公共卫生举措和基础设施建设,用于早期发现痴呆症.
主要成果:
- 显著的全球和国家痴呆症低检测.
- 有明显的诊断不平等影响少数群体和弱势群体的证据.
- 对早期检测对个人和护理人员的好处达成广泛共识.
结论:
- 早期发现痴呆症是一个关键的公共卫生问题,需要全面,协调的行动.
- 公共卫生系统,医疗保健提供和社区组织必须合作,以改善检测.
- 痴呆症早期检测公共卫生卓越中心 (PHCOE on EDD) 作为国家资源,推进基于证据的战略.
相关概念视频
Dementia
480
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
480
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Cognitive Development During Adulthood
737
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
737


